dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pesarrodona, Mireia |
dc.contributor.author | Jauset González, Antoni |
dc.contributor.author | Sánchez-Chardi, Alejandro |
dc.contributor.author | Seras Franzoso, Joaquin |
dc.contributor.author | Baltà Foix, Ricardo |
dc.contributor.author | Mancilla Zamora, Sandra |
dc.contributor.author | Fernández Amurgo, Yolanda |
dc.contributor.author | Schwartz Navarro, Simon |
dc.contributor.author | Abasolo Olaortua, Ibane |
dc.contributor.author | Diaz Riascos, Zamira Vanessa |
dc.contributor.author | Beaulieu, Marie-Eve |
dc.contributor.author | Soucek, Laura |
dc.date.accessioned | 2020-07-29T11:24:49Z |
dc.date.available | 2020-07-29T11:24:49Z |
dc.date.issued | 2019-07-24 |
dc.identifier.citation | Pesarrodona M, Jauset T, Díaz‐Riascos ZV, Sánchez‐Chardi A, Beaulieu M, Seras‐Franzoso J, et al. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci. 2019 Jul 24;6(18):1900849. |
dc.identifier.issn | 2198-3844 |
dc.identifier.uri | https://hdl.handle.net/11351/5119 |
dc.description | Biofabricació; Teràpia contra el càncer; Amiloides funcionals |
dc.description.sponsorship | This study has been supported by La Fundacio Marato TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigacion (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS "NANBIOSIS," more specifically by the Protein Production Platform of CIBER-BBN/IBB () and the Biomaterial Processing and Nanostructuring Unit (), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS "NANBIOSIS," specifically by U20/FVPR (). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award |
dc.language.iso | eng |
dc.publisher | Wiley Online Library |
dc.relation.ispartofseries | Advanced Science;6(18) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Proteïnes recombinants |
dc.subject | Mama - Càncer |
dc.subject | Medicaments antineoplàstics |
dc.subject.mesh | Inclusion Bodies |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Antineoplastic Agents |
dc.title | Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/advs.201900849 |
dc.subject.decs | cuerpos de inclusión |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | antineoplásicos |
dc.relation.publishversion | https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201900849 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Pesarrodona M] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Jauset T, Beaulieu ME] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. [Díaz-Riascos ZV, Mancilla S, Fernández Y, Abasolo I] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Àrea de Validació Funcional i Estudis Preclínics, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Sánchez-Chardi A] Departament de Biologia Evolutiva Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Barcelona Spain. [Seras-Franzoso J, Baltà-Foix R] CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic,, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Schwartz Jr S] CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CIBBIM-Nanomedicina Direccionament i Alliberament Farmacològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Soucek L] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Peptomyc S.L. Edifici Cellex, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 31559131 |
dc.identifier.wos | 000477715600001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F00272 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI17%2F02242 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F01224 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |